We, therefore, stained tumor-infiltrating CD8+ T cells for CD44, a marker expressed on activated antigen-experienced T cells, and observed CD44 positivity in 74.82%±5.4 of CD8+ T cells from tumors treated with triple therapy (RT+L19–IL2+anti-PD-L1). Here, IL2 is linked to neoplasm.